On November 3, 2026, European private equity firm Cinven announced it has agreed to acquire Theramex, the London-based specialty pharmaceutical company focused entirely on women's health, from Carlyle and PAI Partners. Cinven's release says financial terms are not disclosed. The Financial Times and trade press put the deal at about €2.6 billion. FemTech World describes that figure as "reportedly" the price and says completion is expected in the first half of 2027, subject to regulatory approval. (Femtech Insider gave the same number in dollars; we treat the euro figure as the reported price and regard it as unconfirmed by the parties.)

Why It Matters

**Three intimate-health deals in four days, at three very different sizes.** On October 31, Sky News reported that TDR Capital had agreed to buy Lovehoney Group for about €400 million ([*Private Equity Gets Into Bed With Lovehoney*](/stories/tdr-capital-acquires-lovehoney-group)). On November 2, Aspen sold Europe's Ovestin vaginal-estrogen franchise to Ennogen for €197 million ([*Estriol Estate*](/stories/aspen-ovestin-europe-sale-ennogen)). Now a portfolio built on menopause hormones and contraception is changing hands at a reported €2.6 billion. A week earlier Ferring agreed to pay up to $1.38 billion for fertility startup Gameto ([*Hold the Shots*](/stories/ferring-acquires-gameto-fertilo)). On the clinic side, Femtech Insider reports that **Ivy Fertility** has taken over **six former Kindbody locations** in St. Louis, Milwaukee and Chicago and reopened them as **Sage Reproductive Center**. Ivy's own November 2 release confirms the six Sage clinics but doesn't mention Kindbody. Private-equity and pharma buyers are paying for intimate-health assets from pleasure retail up to prescription hormones. **Menopause is the common thread.** Theramex's menopause portfolio is being sold while demand is surging. The FDA has been removing boxed warnings from hormone therapy, US estrogen patches are scarce ([*Patchy Supply*](/stories/estradiol-patch-shortage-fda-action)), and the ACP now recommends hormone therapy as first-line treatment ([our coverage](/stories/acp-menopause-hormone-therapy-first-line)). Theramex operates mostly outside the US, but the same reassessment is happening in Europe. For DTC menopause platforms and intimate-wellness brands, the takeaway is that the best-funded buyers in the category are now large pharma-style platforms building by in-licensing. That makes them likely acquirers or licensing partners for smaller companies with a regulated menopause or sexual-health product, and stronger competitors for everyone else.

Theramex develops, in-licenses and sells treatments in four areas: menopause, osteoporosis, contraception and fertility. FemTech World adds uterine health. According to Cinven, the company has more than 500 employees, sells in more than 80 countries across Europe, Africa, Asia-Pacific and Latin America, and its treatments have reached more than six million women. FemTech World reports 17 direct markets. Theramex's corporate roots go back to 1954, according to Alternatives Watch. This is its second private-equity sale in four years: Carlyle and PAI bought it in 2022, and FemTech World reports that EBITDA more than doubled under their ownership through launches, acquisitions and licensing deals.

Cinven's investment case leans on the undertreatment story. Partner Pontus Pettersson, head of its healthcare team, called women's health "a large and growing area of healthcare that has historically been underserved." Partner Philipp Meyer pointed to Theramex's "track record of in-licensing." Cinven says it will back expansion into new geographies and "a pipeline of value-accretive in-licensing opportunities," with particular unmet need in menopause and osteoporosis. CEO Robert Stewart stays on and says the shared ambition is "to become the global leader in women's health." Latham & Watkins advised the sellers.

Sources

Update — 2026-11-04

Initial entry — story first created.